Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The early assessment of new drugs for Alzheimer's disease remains difficult because of the
lack of predictive end-point. The use of a battery including different parameters could
improve this early development of new drugs. Nevertheless, the interest of such a battery
should previously be validated with the yet marketed AD drugs.